CBC Group's Hasten Biopharmaceutical Expands Portfolio with Celltrion Legacy Products
July 4, 2024, 9:51 pm
CBC Group's Hasten Biopharmaceutical, backed by CBC's unique "investor-operator" model, acquires 14 branded products from Celltrion, marking a strategic move towards international expansion and growth in the healthcare sector.
In a bold move towards global expansion and strategic growth, CBC Group's Hasten Biopharmaceutical has announced the successful acquisition of 14 branded products from Celltrion, a South Korean biopharmaceutical company. This acquisition, facilitated by CBC's hands-on "investor-operator" approach, highlights Hasten's commitment to innovation and expansion in the healthcare industry.
The deal, which grants Hasten the Marketing Authorization Holder (MAH) rights for these 14 products in eight countries and regions across Pan-Asia, including South Korea, Singapore, Thailand, Australia, and China Hong Kong S.A.R., signifies a significant milestone in Hasten's business development and product pipeline enhancement. With a focus on chronic diseases and critical care areas, Hasten aims to broaden its product portfolio with the addition of drugs targeting conditions such as hypertension and diabetes, including well-known brands like Edarbi, Basen, Actos, Blopress, and Nesina.
Fu Wei, CEO of CBC Group, expressed his confidence in the strategic deal, emphasizing CBC's expertise in cross-border buyouts and platform building. He highlighted the success of CBC's active approach in supporting healthcare companies like Hasten in their international expansion efforts, while creating value for both companies and investors. This acquisition reinforces CBC's commitment to building a resilient global health ecosystem and delivering essential healthcare solutions across Pan-Asia and beyond.
Summer Xia, CEO of Hasten, echoed Wei's sentiments, emphasizing the importance of this acquisition in advancing Hasten's globalization trajectory. Partnering with CBC provides Hasten with the opportunity to expand its commercial platform regionally, diversify its product offerings, and pave the way for overseas expansion with high-quality products. Xia emphasized Hasten's dedication to addressing unmet medical needs globally by introducing innovative products, leveraging commercialization capabilities, and optimizing the product portfolio to enhance research and production capabilities.
This strategic move follows a series of key growth developments for CBC and Hasten, including a successful fundraising round in 2023 to support strategic acquisitions and business development. Hasten's previous acquisition of the commercial rights for Rocephin in Mainland China further demonstrates the synergy within the portfolio and the commitment to enhancing patient care outcomes.
CBC Group, headquartered in Singapore, is Asia's largest healthcare-dedicated asset management firm with a focus on platform-building, buyouts, private credit, royalties, and real estate in the healthcare sector. Committed to creating lasting value by integrating global innovations and talents, CBC empowers leading healthcare companies to address unmet medical needs worldwide.
Hasten Biopharmaceutical, established in 2020 and jointly invested by CBC Group, Hefei Industry Investment Group, and Feidong County, is a key player in the biopharmaceutical industry. With a focus on R&D, production, and commercial promotion, Hasten's partnership with CBC underscores its dedication to innovation, growth, and delivering quality healthcare solutions to communities globally.
In conclusion, CBC Group's Hasten Biopharmaceutical's acquisition of 14 Celltrion legacy products marks a significant step towards international expansion and growth in the healthcare sector. With a focus on innovation, strategic partnerships, and a commitment to addressing unmet medical needs, Hasten is poised to make a lasting impact in the global healthcare landscape.
In a bold move towards global expansion and strategic growth, CBC Group's Hasten Biopharmaceutical has announced the successful acquisition of 14 branded products from Celltrion, a South Korean biopharmaceutical company. This acquisition, facilitated by CBC's hands-on "investor-operator" approach, highlights Hasten's commitment to innovation and expansion in the healthcare industry.
The deal, which grants Hasten the Marketing Authorization Holder (MAH) rights for these 14 products in eight countries and regions across Pan-Asia, including South Korea, Singapore, Thailand, Australia, and China Hong Kong S.A.R., signifies a significant milestone in Hasten's business development and product pipeline enhancement. With a focus on chronic diseases and critical care areas, Hasten aims to broaden its product portfolio with the addition of drugs targeting conditions such as hypertension and diabetes, including well-known brands like Edarbi, Basen, Actos, Blopress, and Nesina.
Fu Wei, CEO of CBC Group, expressed his confidence in the strategic deal, emphasizing CBC's expertise in cross-border buyouts and platform building. He highlighted the success of CBC's active approach in supporting healthcare companies like Hasten in their international expansion efforts, while creating value for both companies and investors. This acquisition reinforces CBC's commitment to building a resilient global health ecosystem and delivering essential healthcare solutions across Pan-Asia and beyond.
Summer Xia, CEO of Hasten, echoed Wei's sentiments, emphasizing the importance of this acquisition in advancing Hasten's globalization trajectory. Partnering with CBC provides Hasten with the opportunity to expand its commercial platform regionally, diversify its product offerings, and pave the way for overseas expansion with high-quality products. Xia emphasized Hasten's dedication to addressing unmet medical needs globally by introducing innovative products, leveraging commercialization capabilities, and optimizing the product portfolio to enhance research and production capabilities.
This strategic move follows a series of key growth developments for CBC and Hasten, including a successful fundraising round in 2023 to support strategic acquisitions and business development. Hasten's previous acquisition of the commercial rights for Rocephin in Mainland China further demonstrates the synergy within the portfolio and the commitment to enhancing patient care outcomes.
CBC Group, headquartered in Singapore, is Asia's largest healthcare-dedicated asset management firm with a focus on platform-building, buyouts, private credit, royalties, and real estate in the healthcare sector. Committed to creating lasting value by integrating global innovations and talents, CBC empowers leading healthcare companies to address unmet medical needs worldwide.
Hasten Biopharmaceutical, established in 2020 and jointly invested by CBC Group, Hefei Industry Investment Group, and Feidong County, is a key player in the biopharmaceutical industry. With a focus on R&D, production, and commercial promotion, Hasten's partnership with CBC underscores its dedication to innovation, growth, and delivering quality healthcare solutions to communities globally.
In conclusion, CBC Group's Hasten Biopharmaceutical's acquisition of 14 Celltrion legacy products marks a significant step towards international expansion and growth in the healthcare sector. With a focus on innovation, strategic partnerships, and a commitment to addressing unmet medical needs, Hasten is poised to make a lasting impact in the global healthcare landscape.